10-Q: Sera Prognostics Reports Third Quarter 2024 Financial Results, Focuses on PreTRM Test Commercialization

Sera Prognostics reports a net loss of $7.9 million for the third quarter of 2024, while strategically focusing on commercializing its PreTRM test and reducing operating expenses.

Summary

• Sera Prognostics, a women's health company, reported a net loss of $7.9 million for the three months ended September 30, 2024, compared to a net loss of $7.2 million for the same period in 2023.
• The company's revenue for the quarter was $29,000, a decrease from $42,000 in the prior year's quarter.
• Operating expenses totaled $8.9 million, compared to $8.2 million in the third quarter of 2023.
• Research and development expenses were $3.5 million, consistent with the prior year.
• Selling and marketing expenses decreased to $1.2 million from $1.4 million in the prior year.
• General and administrative expenses increased to $4.2 million from $3.3 million in the prior year.
• For the nine months ended September 30, 2024, the net loss was $24.3 million, compared to $28.3 million for the same period in 2023.
• The company's revenue for the nine-month period was $53,000, a decrease from $265,000 in the prior year.
• Total operating expenses for the nine-month period were $27.3 million, compared to $31.2 million in the prior year.
• As of September 30, 2024, Sera Prognostics had cash, cash equivalents, and available-for-sale securities totaling $74.3 million.
• The company believes its existing financial resources are sufficient to continue operating activities for at least 12 months from the issuance date of the financial statements.
• Sera Prognostics is focusing on commercializing its PreTRM test and has taken steps to reduce operating expenses.
• The company has filed a universal shelf registration on Form S-3, allowing for the sale of up to $100 million in securities.
• A sales agreement with TD Securities (USA) LLC allows for the sale of up to $50 million in Class A common stock through an at-the-market offering program, though no shares have been sold under this agreement as of September 30, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is making efforts to reduce costs and commercialize its product, the financial results show increasing losses and decreasing revenue. The company's future is highly dependent on the success of the PreTRM test and its ability to secure funding, which introduces significant uncertainty.

Positives

• The company has taken steps to significantly reduce annual operating expenses across all aspects of the business.
• Sera Prognostics believes its cash runway is sufficient to enable operations into 2027 based on existing operating plans.
• The company is focusing on accelerating market adoption of the PreTRM test and developing additional pipeline products and services.
• The company has begun marketing and processing whole-blood specimens, which simplifies collection and may lower costs.
• The company is pursuing contracts with private and governmental payers and health systems.
• The company has an effective universal shelf registration on Form S-3, providing flexibility for future capital raises.

Negatives

• The company has incurred net losses since inception and anticipates continuing losses for the foreseeable future.
• Revenue for the quarter was $29,000, a decrease from $42,000 in the prior year's quarter.
• The company has an accumulated deficit of $271.2 million as of September 30, 2024.
• The company's future operations are highly dependent on the commercialization and market acceptance of the PreTRM test.
• The company may need to raise additional funds through equity offerings, debt financings, or other capital sources.
• The company has not sold any shares of Class A common stock under the 2024 Sales Agreement as of September 30, 2024.

Risks

• The company's future success depends on the commercialization and market acceptance of the PreTRM test.
• The company may not be able to achieve significant revenues or profitability to sustain operations.
• The company may be required to delay, scale back, or abandon some or all of its operations if it cannot raise additional funds.
• The company faces competition in the life science industry, including companies engaged in molecular diagnostics and proteomics.
• The company relies on third parties for specimen collection and commercial courier delivery services, which could be disrupted.
• The company relies on a limited number of suppliers for some laboratory instruments and materials.
• The company's ability to utilize net operating loss carryforwards may be limited.
• The company's estimates of total addressable market opportunity and forecasts of market growth may be inaccurate.
• The company may face challenges in obtaining adequate reimbursement from third-party payers.
• The company may be subject to legal claims arising from product liability or professional liability.
• The company's proprietary biobank could be contaminated, lost, or destroyed.
• The company relies on access to internal and external databases, and loss of access could harm the business.
• The company may be subject to changes in laws and regulations, including those related to laboratory licensing and data privacy.
• The company may be subject to claims of intellectual property infringement.
• The company's stock price may be volatile.

Future Outlook

The company expects to incur significant additional operating losses and negative cash flows for the foreseeable future, primarily due to commercialization activities for the PreTRM test and research and development of other pipeline products. The company believes its cash runway is sufficient to enable operations into 2027 based on existing operating plans.

Management Comments

• The company is focusing its efforts to accelerate the market adoption of the PreTRM test and the development and launch of additional pipeline products and services.
• The company will continue to evaluate the allocation of its resources.
• The company believes market adoption by both health care providers and payers should be aided by the recent publication of the AVERT PRETERM TRIAL, as well as upcoming publications related to the PRIME study and real-world evidence studies.

Industry Context

The company operates in the competitive life science industry, specifically in molecular diagnostics and proteomics. The company's focus on women's health and preterm birth prediction aligns with a growing need for improved maternal and neonatal care. The company's efforts to secure payer contracts and demonstrate the clinical and economic utility of its PreTRM test are crucial for its success in this market.

Comparison to Industry Standards

• Sera Prognostics' revenue is significantly lower than established diagnostic companies, reflecting its early commercialization stage.
• The company's net losses are typical for a development-stage biotech company, but the need for additional funding is a key risk.
• The company's focus on proteomics and bioinformatics is aligned with industry trends towards personalized medicine.
• The company's cash position of $74.3 million is relatively modest compared to larger, more established diagnostic companies, highlighting the need for careful cash management and potential future capital raises.
• The company's reliance on a single product, the PreTRM test, is a risk compared to companies with diversified product portfolios.
• The company's efforts to obtain reimbursement and payer contracts are critical, as many diagnostic companies face challenges in this area.
• The company's research and development expenses are consistent with other companies in the biotech space, but the need to demonstrate clinical and economic utility is paramount.

Legal Proceedings

• The company is not currently a party to any material litigation or other material legal proceedings.

Related Party Transactions

• The company has a master services agreement with Carelon Research, a subsidiary of Elevance Health, Inc., for research projects.
• The company has a Laboratory Services Agreement with Elevance Health related to the PRIME study.
• The company has a commercial collaboration agreement with Elevance Health and its affiliates for the use of the PreTRM test.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's need for additional funding.
• Employees may be affected by potential workforce reductions as the company focuses on cost management.
• Customers (healthcare providers and patients) may benefit from the PreTRM test if it achieves broad market adoption and reimbursement.
• Suppliers may be impacted by the company's efforts to reduce costs and streamline its supply chain.
• Payers (insurance companies and government programs) will be affected by the company's efforts to secure coverage and reimbursement for the PreTRM test.

Next Steps

• The company will continue to evaluate the allocation of its resources as it focuses its efforts to accelerate the market adoption of its PreTRM test.
• The company will continue to pursue contracts with private and governmental payers and health systems.
• The company is seeking publication of the PRIME study results in a peer-reviewed journal and submitting an abstract for presentation at a key conference in early 2025.
• The company plans to launch real-world evidence implementation programs in late 2024 or early 2025.

Key Dates

Keywords

PreTRM test, proteomics, bioinformatics, maternal health, preterm birth, biomarker tests, womens health, diagnostics, CLIA-certified laboratory, commercialization